Clinical Evaluation of Safety and Immunogenicity of PADRE-Cytomegalovirus (CMV) and Tetanus-CMV Fusion Peptide Vaccines With or Without PF03512676 Adjuvant

Background. It has been reported that cytomegalovirus (CMV) pp65-specific T cells can protect hematopoietic cell transplant (HCT) recipients from CMV complications. Two candidate CMV peptide vaccines composed of the HLA A*0201 pp65(495-503) cytotoxic CD8(+) T-cell epitope fused to 2 different univer...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: La Rosa, Corinna, Longmate, Jeff, Lacey, Simon F., Kaltcheva, Teodora, Sharan, Rahul, Marsano, Denise, Kwon, Peter, Drake, Jennifer, Williams, Brenda, Denison, Sharon, Broyer, Suenell, Couture, Larry, Nakamura, Ryotaro, Kelsey, Morris I., Krieg, Arthur M., Diamond, Don J., Zaia, John A.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2012
Assuntos:
Major Articles and Brief Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3308906/
https://ncbi.nlm.nih.gov/pubmed/22402037
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jis107
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados